Statistical Considerations for Assessment of Bioanalytical Incurred Sample Reproducibility

Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 3

Abstract

Bioanalytical method validation is generally conducted using standards and quality control (QC) samples which are prepared to be as similar as possible to the study samples (incurred samples) which are to be analyzed. However, there are a variety of circumstances in which the performance of a bioanalytical method when using standards and QCs may not adequately approximate that when using incurred samples. The objective of incurred sample reproducibility (ISR) testing is to demonstrate that a bioanalytical method will produce consistent results from study samples when re-analyzed on a separate occasion. The Third American Association of Pharmaceutical Scientists (AAPS)/Food and Drug Administration (FDA) Bioanalytical Workshop and subsequent workshops have led to widespread industry adoption of the so-called “4–6–20” rule for assessing incurred sample reproducibility (i.e. at least 66.7% of the re-analyzed incurred samples must agree within ±20% of the original result), though the performance of this rule in the context of ISR testing has not yet been evaluated. This paper evaluates the performance of the 4–6–20 rule, provides general recommendations and guidance on appropriate experimental designs and sample sizes for ISR testing, discusses the impact of repeated ISR testing across multiple clinical studies, and proposes alternative acceptance criteria for ISR testing based on formal statistical methodology.

Authors and Affiliations

David Hoffman

Keywords

Related Articles

Cannabinoids, electrophysiology, and retrograde messengers: Challenges for the next 5 years

Most of the behavioral effects of cannabis and its active ingredients, the cannabinoids (Δ9THC being the most abundant of these), appear to be mediated by cannabinoid receptors. Endogenous cannabinoids (endocanna...

Synthesis and Pharmacological Evaluation of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a Cocaine Antagonist, in Rodents

The online version of this article (doi:10.1208/s12248-011-9274-9) contains supplementary material, which is available to authorized users.

Survey of International Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products

The objective of this article is to discuss the similarities and differences in accepted bioequivalence (BE) approaches for generic topical dermatological drug products between international regulatory authorities and or...

Effects of Molecular Weight and Loading on Matrix Metalloproteinase-2 Mediated Release from Poly(Ethylene Glycol) Diacrylate Hydrogels

Herein, we report on continued efforts to understand an implantable poly(ethylene glycol) diacrylate (PEGDA) hydrogel drug delivery system that responds to extracellular enzymes, in particular matrix metalloproteinase-2...

Download PDF file
  • EP ID EP681504
  • DOI  10.1208/s12248-009-9134-z
  • Views 76
  • Downloads 0

How To Cite

David Hoffman (2009). Statistical Considerations for Assessment of Bioanalytical Incurred Sample Reproducibility. The AAPS Journal, 11(3), -. https://europub.co.uk/articles/-A-681504